Table 2 Efficacy results for patients with investigator-defined total spinal ankylosis or Stage V radiographic criteria during the 24-week, double-blind period

Treatment	Entered early escape therapy	Week 12 response				Week 24 response
Treatment	Entered early escape therapy	ASAS20	ASAS40	ASAS 5/6	BASDAI 50	ASAS20	ASAS40	ASAS 5/6	BASDAI 50
ADA*	No	√	√	√	√	√	√	—	√
ADA	No	√	—	—	—	√	—	√	—
ADA	No	√	√	√	—	√	√	√	√
ADA*	No	—	—	—	√	√	—	√	√
ADA*	Yes	—	—	—	—	0	0	0	0
ADA*	Yes	—	—	—	—	0	0	0	0
PBO*	No	—	—	—	—	—	—	—	—
PBO	Yes	—	—	—	—	+	0	0	0
PBO*	Yes	—	—	—	—	+	+	+	+
PBO*	Yes	—	—	—	—	0	0	0	0
PBO*	Yes	—	—	—	—	+	+	+	+

ADA, adalimumab; ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PBO, placebo; √, Responder on blinded therapy; —, non-responder on blinded therapy; +, responder on early escape, open-label adalimumab; 0, non-responder on early escape, open-label adalimumab.
*Patients fulfilling Stage V radiographic criteria for TSA.